Loading
CS
CubeDoc SE Stock: price and insider trades · Germany
CubeDoc SE: what insiders have been doing
CubeDoc SE is a Healthcare & Pharma company. Its directors and officers file their transactions with BaFin. Over the twelve months to 18 October 2026, 14 filings were filed, from 2 insiders.
No insider bought on the market over the period, while 1 insider filed 1 sale totalling €55k. One trade stands out by size: a sale of €55k from Thetis Value GmbH, disclosed on 6 May 2026.
Between a trade and the moment it shows up on BaFin, the median delay is 5 days. The regulation allows three business days to notify a trade (MAR article 19). Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Across the 287 companies tracked on its exchange, the median is 5 filings; at 14 filings, this issuer sits above that mark. Our records for CubeDoc SE go back to 2026, with no purchases and 1 sale on the open market in total.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by BaFin. They describe what insiders did and are not a recommendation.
Insider Decl.
14
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€55,300
1 ops. · all time
Who traded when
BuySaleThetis Value GmbH1 sale
Financial data
· cache
Last declaration on 9 June 2026
Declarations14 total
50,000 shares@ €1.340.2% of flowShareISIN DE000A3DXGY5BAFIN:40036211-791e792e6100
6,500 shares@ €0.600.0% of flowShareISIN DE000A3DXGY5BAFIN:40036211-2464885f9f49
404,761.905 shares@ €0.210.2% of flowShareISIN DE000A3DXGY5BAFIN:40036211-e817d5d3fead
24,500 shares@ €0.600.0% of flowShareISIN DE000A3DXGY5BAFIN:40036211-d5be132d32c8
23,332 shares@ €0.600.0% of flowShareISIN DE000A3DXGY5BAFIN:40036211-ffbcc8861f28
6,667 shares@ €0.600.0% of flowShareISIN DE000A3DXGY5BAFIN:40036211-50e449c364de
226,921.897 shares@ €0.780.4% of flowShareISIN DE000A3DXGY5BAFIN:40036211-7a2f1811f20c
376,666.667 shares@ €0.150.1% of flowShareISIN DE000A3DXGY5BAFIN:40036211-96d98c7153cd
1,100,000 shares@ €0.100.3% of flowShareISIN DE000A3DXGY5BAFIN:40036211-6624813a29f5
119,000 shares@ €0.130.0% of flowShareISIN DE000A3DXGY5BAFIN:40036211-d313d0a940cb
555,000.833 shares@ €0.240.3% of flowShareISIN DE000A3DXGY5BAFIN:40036211-43c4e77cebea
365,590.551 shares@ €1.271.1% of flowShareISIN DE000A3DXGY5BAFIN:40036211-fc4765050048
35,000 shares@ €1.580.1% of flowShareBörse DüsseldorfISIN DE000A3DXGY5BAFIN:40036211-d1954220c643
40,515,000 shares@ €1.0097.1% of flowShareISIN DE000A3DXGY5BAFIN:40036211
14 of 14 declarations
About CubeDoc SE
CubeDoc SE is a German listed company traded on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany, with an investment case centered on the digitalization of access to healthcare. In 2026, the company repositioned itself around a digital medical infrastructure aimed at combining telemedicine, proximity diagnostics, and care services, notably through its “CubeDoc health cube.” According to company disclosures, the first commercial unit was put into operation in Bad Kissingen in April 2026, marking the effective market entry. CubeDoc’s target customer base includes care facilities, pharmacies, retail locations, and other high-traffic sites, with a value proposition built on remote physician consultation and AI-supported basic diagnostics.
CubeDoc’s recent history is essential to understanding the stock. The company was formerly known as UTRANOS SE and went through a major strategic reset in 2026. An extraordinary general meeting approved the shift to a dualistic governance structure, with a management board and supervisory board, while the contribution of CubeDoc GmbH was completed through a capital increase in kind. These transactions allowed CubeDoc SE to fully integrate the operating business and put a governance framework in place for the growth phase.
Read moreShow less
Operationally, the model is modular and scalable, designed as a digitally enabled “mini-practice.” The health cube combines telemedical consultations, collection of vital signs, respiratory testing, cardiovascular checks, and basic laboratory analyses, with patient data transmitted digitally to the physician in real time. The company also emphasizes a hybrid revenue model combining upfront installation revenues, recurring platform income, and additional service-based monetization. CubeDoc says it has already secured binding purchase agreements for more than 50 systems, which provides an initial sign of commercial traction, although the financial track record remains very early-stage.
From a competitive standpoint, CubeDoc operates in the fast-growing telehealth and decentralized medical infrastructure segment, supported by structural drivers such as population aging, shortages in primary care physicians, and rising demand for accessible local healthcare. The company states that it is pursuing rapid scaling in Germany, with international expansion also part of its roadmap. A notable recent event occurred on 13 May 2026, when Hubertus Seidler was appointed as executive director and Nils Behrens was removed from that role, underlining active management of the rollout strategy.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
